Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
ASH 2021 – Systemic Mastocytosis: Wrap-Up
ASH 2021 – Systemic Mastocytosis: Wrap-Up
Preliminary Evidence for Identifying Patterns of Organ Damage in Advanced Systemic Mastocytosis Subtypes
ASH 2021 – Systemic Mastocytosis: Wrap-Up
Criteria to assess presenting patterns of organ damage have not been extensively evaluated. Preliminary evidence suggests identifying these patterns could be useful in profiling organ dysfunction in avapritinib clinical trials.
Read More ›
Cladribine as First-Line Therapy for Indolent and Advanced Systemic Mastocytosis
ASH 2021 – Systemic Mastocytosis: Wrap-Up
Cladribine has long been established as an efficient therapy in systemic mastocytosis and remains a valuable treatment option even as new therapies emerge.
Read More ›
Genetic Testing for Hereditary Alpha-Tryptasemia in Patients Presenting with Mast-Cell Mediator Symptoms in the Absence of Symptoms of Mastocytosis
ASH 2021 – Systemic Mastocytosis: Wrap-Up
Hereditary alpha-tryptasemia may promote development of systemic mastocytosis. Screening for variations in copy number of the alpha tryptase gene may provide early evidence for diagnosis of mastocytosis.
Read More ›
Assessing the Potential Role of Anti-CD117 CAR T-Cells for Targeted Therapy in Advanced Systemic Mastocytosis
ASH 2021 – Systemic Mastocytosis: Wrap-Up
CAR T-cell immunotherapy is highly efficient because of its ability to target specific tumor antigens. Preliminary evidence suggests that CAR T-cells directed against CD117, the KIT receptor, may emerge as a therapeutic option for advanced systemic mastocytosis.
Read More ›
Whole Genome Sequencing Detects Chromosomal Aberrations Associated with Systemic Mastocytosis
ASH 2021 – Systemic Mastocytosis: Wrap-Up
Cytogenetic aberrations are rarely found by cytogenetics in systemic mastocytosis but are associated with advanced disease. Whole genome sequencing detects both chromosomal aberrations and non-
KIT
gene mutations and can be used as an alternative to cytogenetics for assessing disease risk.
Read More ›
PATHFINDER Study Reveals Potential for Avapritinib to Modify Progression of Advanced Systemic Mastocytosis
ASH 2021 – Systemic Mastocytosis: Wrap-Up
Avapritinib was recently approved for treatment in advanced systemic mastocytosis after demonstrating in clinicals trials the ability to improve hematologic and bone marrow responses in patients.
Read More ›
Avapritinib Effectively Manages Advanced Systemic Mastocytosis in Patients with KIT D816V Mutations
ASH 2021 – Systemic Mastocytosis: Wrap-Up
KIT D816V mutations are highly associated with most cases of systemic mastocytosis. Avapritinib demonstrates efficacy in controlling disease progression in patients with
KIT D816V
mutations.
Read More ›
Medicare Patients with Advanced Systemic Mastocytosis Have a Higher Financial Burden and Use More Healthcare Resources
ASH 2021 – Systemic Mastocytosis: Wrap-Up
Advanced systemic mastocytosis often develops in patients aged >60 years but some younger patients qualify for Medicare due to preexisting disability. All patients with advanced systemic mastocytosis require more healthcare resources and have greater medical costs.
Read More ›
Assessment of Prognostic Scoring Tools for Systemic Mastocytosis in a Real-World Setting
ASH 2021 – Systemic Mastocytosis: Wrap-Up
Clinical trials in systemic mastocytosis have led to the development of new prognostic scoring systems. Although effective in a controlled study, their usefulness in identifying high-risk patients in a real-world clinical setting requires further evaluation.
Read More ›
New Study Investigates Safety and Efficacy of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
ASH 2021 – Systemic Mastocytosis: Wrap-Up
Bezuclastinib treatment has shown clinical activity in advanced solid tumors with little toxicity. A phase 2 investigation seeks to determine its potential as a safe and effective option for KIT D816V–driven advanced systemic mastocytosis.
Read More ›
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us